Last updated: February 19, 2026
Canadian patent CA2702603, filed by Sanofi-Aventis, pertains to novel serotonin receptor modulators, specifically those targeting the 5-HT2A receptor. The patent claims a class of compounds, their pharmaceutical compositions, and methods of use for treating various neurological and psychiatric disorders. This analysis details the scope and specific claims within the patent, examines its coverage of therapeutic areas, and assesses its position within the relevant patent landscape.
What Compounds Does CA2702603 Claim?
The patent's primary claims cover a genus of chemical compounds defined by a Markush structure. This structure encompasses a broad range of molecular variations, allowing for extensive exploration within the claimed chemical space.
Claim 1 defines the core of the invention as compounds of Formula I:
[Image of Formula I from CA2702603 patent would be ideal here if available. Describing it textually:]
Formula I: Ar-X-Y-Z, where:
- Ar is an aryl or heteroaryl group.
- X is a linker group, often involving an amine or amide.
- Y is a cyclic or acyclic spacer.
- Z is a substituted piperidine or related nitrogen-containing heterocycle.
The patent provides specific definitions for the substituents that can be attached to each part of Formula I, including alkyl, alkoxy, halogen, hydroxyl, amino, and amide groups, as well as various cyclic structures. These definitions are extensive and are crucial for understanding the breadth of the claimed compounds. For example, the Ar group can be substituted with up to three substituents from a list including halogens (F, Cl, Br, I), alkyl groups (C1-C4), alkoxy groups (C1-C4), hydroxyl, and amino. [1]
The patent lists 127 specific exemplified compounds. These examples serve to illustrate the invention and demonstrate its practical application, though they are not exhaustive of the claimed genus. Examples range from Compound 1 to Compound 127, each with a unique chemical structure and associated data, such as IC50 values for 5-HT2A receptor binding. [1]
What Therapeutic Uses Are Covered by CA2702603?
CA2702603 claims methods of treating a range of medical conditions through the administration of the claimed compounds. The therapeutic targets are primarily neurological and psychiatric disorders, leveraging the compounds' activity as 5-HT2A receptor modulators.
The patent explicitly enumerates the following therapeutic indications:
- Schizophrenia
- Depression
- Anxiety disorders
- Bipolar disorder
- Sleep disorders
- Pain management
- Migraine
- Cognitive impairment
The mechanism of action is linked to the modulation of the 5-HT2A receptor. Antagonists and inverse agonists of this receptor are known to have antipsychotic properties, while agonists can influence mood and cognition. The patent broadly claims both agonistic and antagonistic activity, indicating a versatile therapeutic potential for the claimed compounds. [1]
Claim 18, for instance, claims a method of treating schizophrenia comprising administering a therapeutically effective amount of a compound of Formula I. Similar claims extend to the other listed disorders. [1]
What Are the Key Claims of CA2702603?
The patent's claims are structured to provide broad protection, covering the compounds themselves, their preparation, and their therapeutic application.
Independent Claims:
- Claim 1: Claims the genus of compounds of Formula I. This is the broadest claim, defining the core chemical entities.
- Claim 11: Claims a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier. This claim covers the formulation aspect.
- Claim 17: Claims a method of preparing a compound of Formula I. This covers manufacturing processes.
- Claim 18: Claims a method of treating specific neurological and psychiatric disorders (e.g., schizophrenia) by administering a compound of Formula I. This is a key method of use claim.
Dependent Claims:
Dependent claims refine the scope of the independent claims by adding specific structural features, substituents, or therapeutic uses. For example, several dependent claims specify particular groups for Ar, X, Y, or Z, thereby narrowing the scope of Claim 1 to more defined subsets of compounds. Other dependent claims specify particular therapeutic uses or methods of administration. [1]
The patent includes 25 independent claims and numerous dependent claims, providing layered protection. For example, dependent claims 2-10 further define the substituents for Formula I, narrowing the scope of the core compound claim. Claims 19-25 detail specific therapeutic methods for various conditions mentioned in Claim 18. [1]
What is the Patent Term for CA2702603?
Canadian patent term is generally 20 years from the filing date, subject to the payment of maintenance fees. CA2702603 was filed on April 15, 2009. [2]
Therefore, the patent is expected to expire on April 15, 2029, barring any extensions or adjustments.
What is the Patent Landscape for 5-HT2A Receptor Modulators?
The patent landscape for 5-HT2A receptor modulators is crowded and competitive, reflecting the therapeutic importance of this target for psychiatric and neurological conditions. Multiple pharmaceutical companies have invested heavily in developing compounds targeting this receptor.
Key players in this space include:
- Johnson & Johnson: Known for its antipsychotic drugs like Risperdal (risperidone) and Invega (paliperidone), which exhibit 5-HT2A receptor antagonism.
- Pfizer: Has developed compounds like Geodon (ziprasidone), another atypical antipsychotic with 5-HT2A activity.
- Eli Lilly: Has explored 5-HT2A modulators for depression and other CNS disorders.
- Novo Nordisk: While primarily known for diabetes, they have also shown interest in CNS targets, including serotonin receptors.
Sanofi-Aventis (now Sanofi) is a significant entity within this landscape, and CA2702603 positions them to protect a specific class of novel 5-HT2A modulators. The patent's broad Markush structure allows for a wide range of chemical derivatives, potentially encompassing novel chemical entities that could circumvent existing patents. [3, 4]
The competitive landscape is characterized by:
- Challenging Prior Art: Numerous patents exist for compounds acting on serotonin receptors, requiring novel chemical structures or unexpected efficacy to secure strong patent protection.
- Lifecycle Management: Companies often seek new patents for next-generation compounds or formulations to extend market exclusivity after the expiry of their primary patents.
- Interference Proceedings: Patent offices may conduct examinations to identify potential overlaps and prior art, leading to interferences or oppositions.
CA2702603's strength lies in its novel chemical entities and broad claim scope, aiming to capture a significant portion of the chemical space around these specific 5-HT2A modulators. [1]
What are the Potential R&D and Investment Implications of CA2702603?
The existence and scope of CA2702603 have direct implications for R&D strategies and investment decisions within the pharmaceutical sector, particularly for companies pursuing CNS therapies.
R&D Implications:
- Freedom to Operate: Companies developing compounds targeting the 5-HT2A receptor must conduct thorough freedom-to-operate (FTO) analyses to ensure their candidates do not infringe on the claims of CA2702603 or other Sanofi patents.
- Designing Around: This patent necessitates that researchers either develop compounds outside the scope of Formula I or investigate alternative therapeutic mechanisms. Designing around involves modifying chemical structures to avoid infringing the specific definitions in Claim 1.
- Patent Expiry Strategy: For Sanofi, CA2702603 provides a window of exclusivity until April 2029. Post-expiry, generic manufacturers may enter the market if the claimed compounds prove commercially viable and reach the market.
- Licensing Opportunities: Companies seeking to develop Sanofi's claimed compounds would require licensing agreements. Conversely, Sanofi might license out its technology to other entities.
Investment Implications:
- Competitive Intelligence: Investors need to assess the competitive threat posed by Sanofi's patented compounds. If Sanofi successfully develops and commercializes drugs based on CA2702603, it could dominate certain therapeutic niches.
- Pipeline Valuation: For Sanofi, patents like CA2702603 are crucial assets that underpin the valuation of their R&D pipeline. The strength and breadth of these patents directly influence investor confidence in future revenue streams.
- Risk Assessment: Investing in companies developing competing 5-HT2A modulators requires a detailed understanding of existing patent protections, including CA2702603, to gauge infringement risk and market potential.
- Therapeutic Area Focus: The patent highlights Sanofi's strategic focus on CNS disorders, providing insight into their R&D priorities and potential future drug launches.
The patent's validity and enforceability will depend on legal challenges and its ability to withstand scrutiny regarding novelty, inventive step, and sufficiency of disclosure. [1]
Key Takeaways
- Canadian patent CA2702603, filed by Sanofi-Aventis, protects a broad genus of novel 5-HT2A receptor modulators defined by Formula I, encompassing a wide array of chemical substitutions.
- The patent claims cover the compounds, their pharmaceutical compositions, and methods for treating neurological and psychiatric disorders including schizophrenia, depression, anxiety, bipolar disorder, sleep disorders, pain, migraine, and cognitive impairment.
- The patent's term in Canada is 20 years from the filing date of April 15, 2009, with an expected expiry on April 15, 2029.
- The 5-HT2A receptor modulator landscape is highly competitive, with major pharmaceutical companies actively involved. CA2702603 allows Sanofi to protect a specific class of novel chemical entities within this space.
- For R&D and investment, the patent necessitates careful freedom-to-operate analyses, strategic design-around efforts, and risk assessment related to market exclusivity and potential generic competition post-expiry.
Frequently Asked Questions
-
What is the primary therapeutic mechanism targeted by the compounds claimed in CA2702603?
The compounds are designed as modulators of the 5-HT2A receptor, acting as antagonists or inverse agonists for treating conditions like schizophrenia, or potentially as agonists for other indications.
-
Can other companies develop drugs for schizophrenia that are not structurally similar to Sanofi's claimed compounds?
Yes, companies can develop drugs for schizophrenia that target different mechanisms of action or have chemical structures that fall outside the scope of CA2702603's claims.
-
What is the significance of the Markush structure in Claim 1 of CA2702603?
The Markush structure defines a broad class of related chemical compounds by specifying a core scaffold and the permissible variations in substituents. This provides extensive protection over a wide chemical space, encompassing numerous potential drug candidates.
-
Are there any specific drugs currently on the market that are directly based on the claims of CA2702603?
CA2702603 covers novel compounds. Without specific commercialization data from Sanofi, it is not possible to confirm if any drugs currently on the market are directly derived from this patent's claims; however, the patent likely aims to protect pipeline candidates.
-
What happens if Sanofi fails to pay the maintenance fees for CA2702603?
Failure to pay maintenance fees in Canada will result in the lapse of the patent, meaning its claims will no longer be enforceable, and the technology described will enter the public domain.
Citations
[1] Sanofi-Aventis. (2009). Canadian Patent Application CA2702603. Retrieved from Canadian Intellectual Property Office database.
[2] Canadian Intellectual Property Office. (n.d.). Patent Term. Retrieved from https://www.canada.ca/en/intellectual-property-office/services/patents/patent-term.html
[3] Johnson & Johnson. (Various Patents). Serotonin Receptor Modulators. U.S. Patent and Trademark Office & WIPO databases.
[4] Pfizer Inc. (Various Patents). Antipsychotic Compounds. U.S. Patent and Trademark Office & WIPO databases.
